Sign In
Buy NKTR
Nektar Therapeutics Earnings Calls
| Release date | Aug 06, 2026 |
| EPS estimate | -$2.05 |
| EPS actual | - |
| Revenue estimate | 10.378M |
| Revenue actual | - |
| Expected change | +/- 7.15% |
| Release date | May 07, 2026 |
| EPS estimate | -$1.58 |
| EPS actual | -$1.82 |
| EPS Surprise | -15.02% |
| Revenue estimate | 10.691M |
| Revenue actual | 10.861M |
| Revenue Surprise | 1.59% |
| Release date | Mar 12, 2026 |
| EPS estimate | -$2.76 |
| EPS actual | -$1.78 |
| EPS Surprise | 35.51% |
| Revenue estimate | 10.19M |
| Revenue actual | 21.807M |
| Revenue Surprise | 114.01% |
| Release date | Nov 06, 2025 |
| EPS estimate | -$2.85 |
| EPS actual | -$1.85 |
| EPS Surprise | 35.09% |
| Revenue estimate | 10.439M |
| Revenue actual | 11.79M |
| Revenue Surprise | 12.94% |
Last 4 Quarters for Nektar Therapeutics
Below you can see how NKTR performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Nov 06, 2025 |
| Price on release | $55.12 |
| EPS estimate | -$2.85 |
| EPS actual | -$1.85 |
| EPS surprise | 35.09% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $64.93 |
| Nov 03, 2025 | $59.92 |
| Nov 04, 2025 | $56.02 |
| Nov 05, 2025 | $54.26 |
| Nov 06, 2025 | $55.12 |
| Nov 07, 2025 | $55.97 |
| Nov 10, 2025 | $57.97 |
| Nov 11, 2025 | $59.26 |
| Nov 12, 2025 | $57.67 |
| 4 days before | -15.11% |
| 4 days after | 4.63% |
| On release day | 1.54% |
| Change in period | -11.18% |
| Release date | Mar 12, 2026 |
| Price on release | $70.36 |
| EPS estimate | -$2.76 |
| EPS actual | -$1.78 |
| EPS surprise | 35.51% |
| Date | Price |
|---|---|
| Mar 06, 2026 | $70.70 |
| Mar 09, 2026 | $69.15 |
| Mar 10, 2026 | $72.07 |
| Mar 11, 2026 | $73.33 |
| Mar 12, 2026 | $70.36 |
| Mar 13, 2026 | $73.25 |
| Mar 16, 2026 | $72.21 |
| Mar 17, 2026 | $75.06 |
| Mar 18, 2026 | $73.18 |
| 4 days before | -0.481% |
| 4 days after | 4.01% |
| On release day | 4.11% |
| Change in period | 3.51% |
| Release date | May 07, 2026 |
| Price on release | $83.37 |
| EPS estimate | -$1.58 |
| EPS actual | -$1.82 |
| EPS surprise | -15.02% |
| Date | Price |
|---|---|
| May 01, 2026 | $86.46 |
| May 04, 2026 | $86.89 |
| May 05, 2026 | $84.16 |
| May 06, 2026 | $85.09 |
| May 07, 2026 | $83.37 |
| May 08, 2026 | $81.89 |
| May 11, 2026 | $78.72 |
| May 12, 2026 | $78.43 |
| May 13, 2026 | $75.95 |
| 4 days before | -3.57% |
| 4 days after | -8.90% |
| On release day | -1.78% |
| Change in period | -12.16% |
| Release date | Aug 06, 2026 |
| Price on release | - |
| EPS estimate | -$2.05 |
| EPS actual | - |
| Date | Price |
|---|---|
| Jul 07, 2026 | $74.90 |
| Jul 08, 2026 | $71.90 |
| Jul 09, 2026 | $72.92 |
| Jul 10, 2026 | $70.36 |
| Jul 13, 2026 | $68.32 |
Nektar Therapeutics Earnings Call Transcript Summary of Q1 2026
Nektar reported strong Phase II data for REZPEG in atopic dermatitis (AD) and alopecia areata (AA) showing deepening efficacy over time, favorable safety, and the potential for infrequent maintenance dosing (monthly or quarterly). Management will initiate the ZENITH-AD global Phase III AD program by July 2026 (three trials: two biologic‑naive pivotal studies and one biologic‑experienced study), with first Phase III readouts expected mid‑2028 and a target BLA submission in 2029. A Phase III program in AA is planned to begin in early 2027 with a likely 52‑week pivotal design; Phase II 52‑week extension data supported additional responders with continued dosing. REZPEG showed a potentially unique benefit on asthma control in AD (ACQ‑5 improvement) and may offer a differentiated safety profile versus JAK inhibitors in AA. The company is pursuing additional indications (including a TrialNet‑sponsored T1D study and other proof‑of‑concept work in 2H‑2026) and advancing next‑generation Treg programs (NKTR‑0165/0166). Financially, Nektar strengthened its balance sheet through financings, has over $1 billion in cash and investments after April transactions, and expects cash runway into Q3 2028 and year‑end 2026 cash of $800–825M. R&D and G&A spend are expected to increase as Phase III activity ramps.
